Advice
in the absence of a submission from the holder of the marketing authorisation:
melatonin (Slenyto®) is not recommended for use within NHSScotland.
Indication under review: treatment of insomnia in children and adolescents aged 6-17 years with attention-deficit hyperactivity disorder (ADHD) where sleep hygiene measures have been insufficient.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.
As a result, we cannot recommend its use within NHSScotland.
Download detailed advice280KB (PDF)
Medicine details
- Medicine name:
- melatonin (Slenyto)
- SMC ID:
- SMC2882
- Indication:
-
Treatment of insomnia in children and adolescents aged 6-17 years with attention-deficit hyperactivity disorder (ADHD) where sleep hygiene measures have been insufficient.
- Pharmaceutical company
- Flynn Pharma Ltd
- BNF chapter
- Central nervous system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 10 November 2025